公开(公告)号：US20140296291A1

公开(公告)日：2014-10-02

申请号：US14233444

申请日：2012-06-07

申请人： AMPLIO PHARMA, LLC

发明人： Scott L. Childs ,  Shreenivas R. Lingireddy ,  Nathan Barishansky

IPC分类号： C07D401/04 ,  C07C59/255 ,  C07C55/07 ,  C07C55/08 ,  C07C275/02 ,  C07C65/03

CPC分类号： C07D401/04 ,  A61K31/4035 ,  C07B2200/13 ,  C07C55/07 ,  C07C55/08 ,  C07C59/255 ,  C07C65/03 ,  C07C69/84 ,  C07C275/02

摘要： The invention relates to novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione, including a novel urea cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; a novel gallic acid cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; a novel propyl gallate cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; and a novel L-tartaric acid cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention are described. The invention also relates to pharmaceutical compositions containing the novel crystalline forms, and the therapeutic use of the novel crystalline forms.

摘要翻译： 本发明涉及3-（4-氨基-1-氧代-1,3-二氢 - 异吲哚-2-基） - 哌啶-2,6-二酮的新型结晶形式，其包括3-（4- 氨基-1-氧代-1,3-二氢 - 异吲哚-2-基） - 哌啶-2,6-二酮; 3-（4-氨基-1-氧代-1,3-二氢 - 异吲哚-2-基） - 哌啶-2,6-二酮的新颖的没食子酸共结晶; 3-（4-氨基-1-氧代-1,3-二氢 - 异吲哚-2-基） - 哌啶-2,6-二酮的新颖的没食子酸丙酯共结晶; 和3-（4-氨基-1-氧代-1,3-二氢 - 异吲哚-2-基） - 哌啶-2,6-二酮的新型L-酒石酸共结晶。 描述根据本发明的各种实施方案的新型结晶形式的制备和表征。 本发明还涉及含有新结晶形式的药物组合物，以及新型结晶形式的治疗用途。

公开(公告)号：US10100032B2

公开(公告)日：2018-10-16

申请号：US15367808

申请日：2016-12-02

申请人： AMPLIO PHARMA, LLC

发明人： Scott L. Childs ,  Shreenivas R. Lingireddy ,  Nathan Barishansky

IPC分类号： C07D401/04 ,  A61K31/4035 ,  C07C55/07 ,  C07C55/08 ,  C07C59/255 ,  C07C65/03 ,  C07C275/02 ,  C07C69/84

摘要： The invention relates to novel crystalline forms of 3-(4-amino-l-oxo-l,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione, including a novel urea cocrystal of 3-(4-amino-l-oxo-l,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; a novel gallic acid cocrystal of 3-(4-amino-l-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; a novel propyl gallate cocrystal of 3-(4-amino-l-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; and a novel L-tartaric acid cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention are described. The invention also relates to pharmaceutical compositions containing the novel crystalline forms, and the therapeutic use of the novel crystalline forms.